Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Responding to the Call to Action: Framework to Accelerate Clinical Data Generation for Antiretroviral Use in Pregnant Individuals with HIV.
Vannappagari V, McCallister S, Romach B, Bush M, Stanislaus D, Root C, Lampkin C, Nwokolo N, Puga A, Moreira S, Salem F, DeMasi R, Payvandi N, Smith K, Garges H, de Ruiter A. Vannappagari V, et al. Among authors: smith k. Infect Dis Ther. 2024 Jul;13(7):1391-1398. doi: 10.1007/s40121-024-00993-4. Epub 2024 May 22. Infect Dis Ther. 2024. PMID: 38772986 Free PMC article. No abstract available.
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial.
Ramgopal MN, Castagna A, Cazanave C, Diaz-Brito V, Dretler R, Oka S, Osiyemi O, Walmsley S, Sims J, Di Perri G, Sutton K, Sutherland-Phillips D, Berni A, Latham CL, Zhang F, D'Amico R, Pascual Bernáldez M, Van Solingen-Ristea R, Van Eygen V, Patel P, Chounta V, Spreen WR, Garges HP, Smith K, van Wyk J. Ramgopal MN, et al. Among authors: smith k. Lancet HIV. 2023 Sep;10(9):e566-e577. doi: 10.1016/S2352-3018(23)00136-4. Epub 2023 Aug 8. Lancet HIV. 2023. PMID: 37567205 Clinical Trial.
Correction for Underwood et al., "Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study".
Underwood M, Horton J, Nangle K, Hopking J, Smith K, Aboud M, Wynne B, Sievers J, Stewart EL, Wang R. Underwood M, et al. Among authors: smith k. Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0032622. doi: 10.1128/aac.00326-22. Epub 2023 Feb 16. Antimicrob Agents Chemother. 2023. PMID: 36794938 Free PMC article. No abstract available.
Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.
De Wit S, Bonnet F, Osiyemi O, Bisshop F, Olalla J, Routy JP, Wyen C, Moodley R, Pappa K, Wang R, Oyee J, Saggu P, Letang E, Wynne B, Jones B, Smith KY, Ait-Khaled M. De Wit S, et al. Among authors: smith ky. J Acquir Immune Defic Syndr. 2024 Mar 1. doi: 10.1097/QAI.0000000000003395. Online ahead of print. J Acquir Immune Defic Syndr. 2024. PMID: 38346427
Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study.
Alves K, Kotloff K, McClelland RS, Kouassi A, Plested JS, Kalkeri R, Zhu M, Cloney-Clark S, Cai Z, Smith K, Kaba M, Nelson J, Hammershaimb EA, Mallory RM, Noriega F; 2019nCoV-313 Study Investigators. Alves K, et al. Among authors: smith k. Lancet Infect Dis. 2025 Jan 14:S1473-3099(24)00670-4. doi: 10.1016/S1473-3099(24)00670-4. Online ahead of print. Lancet Infect Dis. 2025. PMID: 39824198
14,435 results
You have reached the last available page of results. Please see the User Guide for more information.